Smart, Safe, Saxy Choice: Why FDA Selected Onglyza for Mini-Sentinel Project

FDA has a lot at stake in the first tangible drug surveillance project through Mini-Sentinel and a lot of audiences to please: Congress, regulated industry, academia, the drug safety community, media and general public. Here is how FDA explained the choice of saxagliptin as the first focus of the project.